While total MEK5 and ERK5 protein expressions in patients has been reported at 50% and 20% respectively, the prevalence of phospho-ERK5 in clinical breast cancer has not yet been investigated by immuno-histochemistry. The gene discussed is MAP2K5; the disease is breast cancer.